Skip to main content
ROVI Subsidiaries
Spain
Germany
France
Italy
Poland
Portugal
United Kingdom
Language
Spanish
Spanish
English
English
English
Español
Home
ROVI
History
Group structure
Business units
International expansion
Strategy
Licenses
Contact
Products
Prescription Pharmaceuticals
Hospital Products
Manufacturing
CDMO
Own product Manufacturing
R&D
Shareholders and Investors
The share
Investor's Calendar
News
Financial and Business Information
CMNV Communications
ESG
Corporate Governance
Telematic assistance access
Prior Registration On-Line Attendance
On-Line Attendance
Sustainability
Responsible governance
Commitment to people
Environmental Commitment
Ethics Channel
Media
FAQS
News
ROVI up to date
Contact
Work with Us
TELEMATIC ASSISTANCE ACCESS
Home
News
ROVI announces the agreement with Hikma to distribute and market its Enoxaparin biosimilar
Tue, 24/04/2018 - 09:49
0 min
Español
NoticiasWeb_English_0.png
Download related document
Select rating
Give ROVI announces the agreement with Hikma to distribute and market its Enoxaparin biosimilar 1/5
Give ROVI announces the agreement with Hikma to distribute and market its Enoxaparin biosimilar 2/5
Give ROVI announces the agreement with Hikma to distribute and market its Enoxaparin biosimilar 3/5
Give ROVI announces the agreement with Hikma to distribute and market its Enoxaparin biosimilar 4/5
Give ROVI announces the agreement with Hikma to distribute and market its Enoxaparin biosimilar 5/5
No votes yet
Related
ROVI takes first place in the Sustainalytics world ESG risk ranking for the...
ROVI takes first place in the Sustainalytics world ESG risk ranking for the second year running Laboratorios Farmacéuticos...
3 min
04/08/2023
ROVI informs on the evaluation process to obtain marketing authorisation for...
ROVI informs on the evaluation process to obtain marketing authorisation for Risvan® The United States Food and Drug Administration (...
1 min
28/07/2023
First half 2023 results press release
ROVI ACHIEVED STABLE TOTAL REVENUE OF 381.0 MILLION EUROS IN THE FIRST POST-PANDEMIC HALF YEAR Operating revenue remained stable,...
4 min
26/07/2023
See More
Email
Facebook
Twitter
LinkedIn
NoticiasWeb_English_0.png